|
Jul 23
|
Peptic Ulcer Drugs Market Forecast Report 2025-2034 | FDA Approves New Helicobacter pylori Treatment; Market Growth Expected
|
|
Jul 22
|
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
|
|
Jul 22
|
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
|
|
Jul 22
|
Sanofi to acquire vaccine biotech in billion-dollar deal
|
|
Jul 22
|
Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion
|
|
Jul 22
|
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
|
|
Jul 22
|
Sanofi to Acquire UK Biotech Vicebio for $1.15 Billion to Bolster Respiratory Vaccine Pipeline
|
|
Jul 22
|
Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion
|
|
Jul 22
|
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
|
|
Jul 22
|
NYC Council's Firewall Starts in District 5--with a Bombshell Named Alina
|
|
Jul 21
|
Sanofi (SNY) Expands Rare Disease Reach With $9.5B Blueprint Deal
|
|
Jul 21
|
SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-Bell
|
|
Jul 21
|
Sanofi concludes Blueprint Medicines acquisition
|
|
Jun 15
|
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
|
|
Jun 15
|
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
|
|
Jun 15
|
Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
|
|
Jun 15
|
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
|
|
Jun 12
|
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 10
|
Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand
|